List of Excipients in Branded Drug SUGAMMADEX

Generic Drugs Containing SUGAMMADEX

Company	Ingredient	NDC	Excipient
B Braun Medical Inc	sugammadex	0264-8200	HYDROCHLORIC ACID
B Braun Medical Inc	sugammadex	0264-8200	SODIUM HYDROXIDE
B Braun Medical Inc	sugammadex	0264-8200	WATER
Hikma Pharmaceuticals USA Inc	sugammadex	0641-6270	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	sugammadex	0641-6270	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	sugammadex	0641-6270	WATER
Sandoz Inc	sugammadex	0781-3468	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in SUGAMMADEX?

# Of NDCs	Excipient
17	HYDROCHLORIC ACID
17	SODIUM HYDROXIDE
16	WATER

Sugammadex Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: September 29, 2026

Sugammadex has a narrow excipient profile because it is an intravenous, high-dose cyclodextrin-based reversal agent. The commercial opportunity is not broad reformulation. It is concentrated in low-risk generic development, container-closure optimization, supply-chain control, differentiated presentations, and manufacturing efficiency.

The reference product, Bridion, is sugammadex injection at 100 mg/mL. Its U.S. formulation uses water for injection with hydrochloric acid and/or sodium hydroxide for pH adjustment. The limited excipient system reduces formulation differentiation but also lowers development complexity for generic manufacturers (U.S. Food and Drug Administration [FDA], 2023a).

What excipients are used in sugammadex injection?

The U.S. Bridion formulation contains sugammadex sodium in water for injection. Hydrochloric acid and sodium hydroxide are used to adjust pH. The product does not rely on preservatives, surfactants, sugars, or amino-acid stabilizers in the labeled formulation (FDA, 2023a).

Attribute	Bridion reference formulation
Active ingredient	Sugammadex sodium
Strength	100 mg/mL
Route	Intravenous
Primary solvent	Water for injection
pH adjustment	Hydrochloric acid and/or sodium hydroxide
Preservative	None listed
Surfactant	None listed
Common presentations	200 mg/2 mL and 500 mg/5 mL single-dose vials
Therapeutic use	Reversal of rocuronium- or vecuronium-induced neuromuscular blockade

Sugammadex is itself a modified gamma-cyclodextrin. It encapsulates aminosteroid neuromuscular blockers in plasma, reducing the need for an excipient system designed to solubilize a conventional small molecule. This structure limits the technical rationale for adding solubilizers or complexing agents.

Why is the excipient system intentionally simple?

The formulation is administered intravenously and may be delivered at doses of 2, 4, or 16 mg/kg, depending on the depth of neuromuscular blockade. At these doses, excipient exposure can become commercially and clinically relevant. A simple aqueous formulation reduces:

• Risk of hypersensitivity or infusion reactions
• Toxicological burden at high dose
• Compatibility problems with hospital admixture systems
• Manufacturing complexity
• Regulatory differences between reference and generic products
• Risk of precipitation or competitive complexation

The principal formulation challenge is maintaining the active ingredient in a stable, sterile, injectable aqueous state rather than improving solubility.

What formulation properties matter most for sugammadex?

The highest-value formulation attributes are pH, osmolality, concentration, chemical stability, container compatibility, and particulate control.

pH and chemical stability

The commercial product is formulated near physiologic pH. The pH-control system must remain effective over the product shelf life without causing degradation or excessive local irritation. Hydrochloric acid and sodium hydroxide are therefore functional processing excipients rather than differentiated formulation components.

Manufacturers should characterize:

• pH drift during accelerated and long-term storage
• Formation of degradation products
• Interaction between sugammadex sodium and container surfaces
• Stability after vial puncture
• Compatibility with common IV administration materials

A generic formulation that uses the same qualitative excipient system has a lower regulatory and clinical risk profile than one that introduces a novel buffer or stabilizer.

Osmolality and injection volume

Sugammadex is supplied at 100 mg/mL. The formulation must support administration through standard hospital intravenous systems while limiting injection volume. A 16 mg/kg reversal dose can require a substantial volume in larger patients. Maintaining the reference concentration is therefore commercially important.

A lower-concentration product could create a volume disadvantage. A higher-concentration product could require additional extractables, viscosity, particulate, and administration studies. Unless a new concentration solves a clear hospital-use problem, the 100 mg/mL presentation is the lower-risk commercial target.

Container-closure compatibility

The preferred development path is a single-dose glass vial with an elastomeric stopper comparable to the reference presentation. Extractables and leachables studies should focus on:

• Bromobutyl or chlorobutyl stopper composition
• Silicone oil and tungsten residues
• Rubber fragment generation
• Adsorption of sugammadex to glass or polymer surfaces
• Closure integrity after sterilization and storage

A polymer container or prefilled syringe could improve workflow but would require a stronger commercial justification. The product’s high dose and emergency-use setting make ready-to-use delivery commercially attractive, but the presentation must preserve stability and minimize waste.

What excipient strategy is best for a generic sugammadex product?

The strongest generic strategy is formulation conservatism.

Development choice	Commercial assessment
Water for injection with pH adjustment	Lowest regulatory and technical risk
Phosphate or citrate buffer	Limited benefit; may introduce compatibility and toxicity questions
Preservative-containing multidose vial	Poor fit for high-value injectable use and single-dose reference product
Surfactant addition	Usually unnecessary and may add safety and leachables risk
Lyophilized product	Unlikely to improve the established liquid presentation
Prefilled syringe	Potential workflow advantage but higher device and stability burden
Ready-to-use small-volume vial	Strongest near-term commercial opportunity
Larger institutional vial	Possible procurement advantage but higher wastage risk
Alternative primary container	Differentiation opportunity with substantial validation requirements

A formulation that matches the reference excipient profile can generally be positioned around supply reliability, price, vial sizes, packaging, and hospital procurement rather than new clinical claims.

What patents protect sugammadex and its formulations?

The core intellectual-property estate historically centered on modified gamma-cyclodextrins and their use to reverse neuromuscular blockade. A principal U.S. patent associated with sugammadex is U.S. Patent No. 6,670,356, covering modified cyclodextrin compounds and related applications (U.S. Patent No. 6,670,356, 2003).

Core composition patents

The original composition and use patents provided the principal barrier to generic entry before U.S. patent expiry. The relevant protection focused on:

• Modified gamma-cyclodextrin structures
• Sugammadex and related derivatives
• Complex formation with rocuronium and vecuronium
• Reversal of neuromuscular blockade

The main U.S. composition patent term ended around 2020, subject to applicable patent-term adjustment. FDA approval of Bridion occurred on December 15, 2015. New chemical entity exclusivity therefore ran for five years, with pediatric exclusivity extending the period by six months where granted, taking regulatory exclusivity into approximately mid-2021 (FDA, 2015; FDA, 2023b).

Formulation and method-of-use patents

Later patent activity may cover:

• Specific concentrations
• pH ranges
• Administration methods
• Use in particular surgical or patient populations
• Dosing based on neuromuscular blockade depth
• Combination use with anesthetic protocols
• Manufacturing and purification methods
• Solid forms or impurity-control processes

These claims are generally narrower than the original composition claims. Their commercial value depends on whether they are listed in the Orange Book, survive validity and infringement challenges, and cover commercially necessary product characteristics.

What is the Orange Book status of sugammadex?

Sugammadex is an FDA-approved small-molecule injectable drug. It is not a biologic and does not follow the biosimilar pathway. Generic manufacturers use the abbreviated new drug application pathway, typically with a bioequivalence and pharmaceutical-equivalence strategy rather than a clinical efficacy trial.

The FDA Orange Book remains the controlling source for:

• Reference listed drug status
• Listed patents
• Patent-use codes
• Approved generic applications
• Therapeutic-equivalence codes
• Patent delisting and expiration information

The regulatory risk is therefore conventional generic-drug risk. The central issues are patent certification, product sameness, injectable quality, and manufacturing control rather than biosimilar interchangeability (FDA, 2024).

When did sugammadex lose exclusivity?

Milestone	Date or period
Bridion U.S. approval	December 15, 2015
Five-year NCE exclusivity	Approximately December 2020
Pediatric extension, where applicable	Approximately June 2021
Core U.S. composition patent protection	Generally expired around 2020
Generic-entry window	Began after applicable patent and exclusivity barriers ended
Current competitive model	ANDA-driven generic competition

The commercial transition was driven by the combination of patent expiry and the end of regulatory exclusivity. Because the formulation is simple and the reference concentration is established, generic manufacturers can pursue a relatively direct development pathway.

Which companies are challenging sugammadex exclusivity?

Sugammadex generic competition has involved major injectable-drug manufacturers and specialty generic companies pursuing ANDA approvals. Companies associated with generic development or litigation activity have included Amneal, Apotex, Dr. Reddy’s, Fresenius Kabi, Hikma, and other injectable manufacturers.

The relevant legal activity has centered on:

• Paragraph IV certifications against listed patents
• Declaratory and infringement litigation
• Settlement agreements governing launch timing
• Product approval timing after patent expiry
• Commercial launch decisions by authorized or independent generic suppliers

Paragraph IV litigation is commercially important even after a patent’s expected expiry because a first filer may obtain 180-day generic exclusivity. The value of that position depends on whether other ANDA applicants are blocked, whether litigation resolves before trial, and whether settlement terms permit an earlier launch.

What patent litigation affects generic sugammadex entry?

Sugammadex litigation risk is concentrated in the period before core composition protection expired. The standard dispute structure involved reference-product patent holders asserting listed patents against ANDA applicants that certified the patents invalid, unenforceable, or not infringed.

For a generic manufacturer, the key diligence questions are:

1. Which patents were listed for the reference product?
2. Which patents received Paragraph IV certifications?
3. Did the patent holder sue within the statutory period?
4. Did a 30-month stay apply?
5. Did the parties enter a settlement?
6. Does the settlement permit an agreed launch date?
7. Are later patents directed to formulation, process, or method of use?

Settlement agreements can create staggered entry. That structure may allow several manufacturers to enter before final expiry while preserving a temporary premium for an earlier filer.

How strong is the sugammadex patent estate?

The patent estate is strongest for the original active structure and its pharmacologic use. It is weaker for routine aqueous formulations that use water for injection and simple pH adjustment.

Patent category	Relative strength after core expiry	Commercial impact
Modified gamma-cyclodextrin composition	Low after expiry	Historical barrier to all generic entry
Complex formation with rocuronium or vecuronium	Low to moderate, depending on claim scope	May affect method-of-use claims
Specific pH or concentration	Moderate if narrowly claimed and listed	Can create targeted litigation risk
Manufacturing process	Moderate	Can raise cost or require alternative process development
Container or device	Moderate	Relevant to differentiated presentations
Hospital administration method	Generally limited	Depends on enforceability and listing status
Basic water-based injectable formulation	Low	Easy to design around if unclaimed

The remaining defensibility is more likely to arise from manufacturing know-how, impurity specifications, supply contracts, regulatory execution, and customer relationships than from broad formulation patents.

What commercial opportunities exist in sugammadex excipients?

The opportunity is primarily in supporting technologies and manufacturing inputs rather than novel excipients.

1. High-purity injectable-grade raw materials

Suppliers can compete in:

• Water-for-injection systems
• Hydrochloric acid and sodium hydroxide qualified for parenteral use
• Low-extractables elastomeric closures
• Type I glass vials
• Sterile filtration assemblies
• Packaging components with validated container-closure integrity

These products can win through qualification, supply continuity, regional manufacturing, and cost control.

2. Container-closure systems

A ready-to-use vial optimized for operating-room workflows can create procurement value. Potential improvements include:

• Clear labeling for rapid dose selection
• Low-overfill configurations
• Tamper-evident packaging
• Reduced stopper fragmentation
• Improved withdrawal performance
• Unit-dose packaging for automated dispensing cabinets

The commercial case is strongest where hospitals incur substantial waste from unused injectable products or experience shortages of branded reversal agents.

3. Prefilled syringes and device presentations

A prefilled syringe could reduce preparation time and dosing errors. It would also create additional regulatory requirements for:

• Device compatibility
• Syringe extractables and leachables
• Silicone and lubricant control
• Needle or connector compatibility
• Stability in the filled device
• Human-factors validation

This is a higher-investment opportunity than a conventional vial but could support premium pricing in ambulatory surgery centers and high-throughput operating rooms.

4. Regional supply and contract manufacturing

Sugammadex demand is concentrated in hospitals, anesthesia departments, and surgical centers. Manufacturers with sterile-fill capacity can use the product as an anchor for a broader anesthesia portfolio.

The strongest operating model combines:

• Qualified cyclodextrin drug substance
• Reliable sterile filling
• Dual-source packaging
• Regional regulatory approvals
• Hospital contract coverage
• Inventory positioned near major surgical markets

5. Formulation and process analytics

Analytical suppliers can support:

• Related-substance testing
• Complexation assays
• Residual solvent testing
• Subvisible particulate testing
• Container-closure integrity
• Stability-indicating methods
• Extractables and leachables programs

These services are commercially relevant because injectable generic approval depends heavily on process consistency and batch release.

How does sugammadex compare with neostigmine?

Sugammadex competes primarily with neostigmine-based reversal regimens.

Factor	Sugammadex	Neostigmine
Mechanism	Encapsulates rocuronium or vecuronium	Inhibits acetylcholinesterase
Formulation	Simple aqueous injectable	Injectable formulation often used with anticholinergic co-medication
Dose predictability	Stronger at deep blockade when appropriately dosed	More dependent on blockade depth
Excipient opportunity	Limited	Broader potential across combination and presentation strategies
Patent risk	Generic-entry risk after core expiry	Mature generic market
Commercial differentiation	Vial, syringe, supply, price, workflow	Combination packaging and protocol economics

Sugammadex has a stronger formulation simplicity advantage but a narrower excipient differentiation opportunity. Neostigmine products may offer more room for combination packaging, ready-to-administer formats, or hospital protocol products.

What generic launch risks exist for sugammadex?

Generic entrants face five principal risks:

1. Injectable manufacturing failures, including particulate or sterility deviations.
2. Drug-substance supply constraints for high-purity modified cyclodextrin.
3. Price erosion after multiple ANDA launches.
4. Hospital conversion friction caused by formulary contracts and anesthesia protocols.
5. Product liability exposure tied to hypersensitivity, dosing errors, or inadequate reversal.

The most defensible generic strategy is a reliable 100 mg/mL vial supported by strong sterile manufacturing, competitive pricing, and dependable supply. Novel excipients are unlikely to compensate for weak manufacturing economics.

What is the revenue exposure for the reference product?

Merck reported Bridion sales of approximately $1.5 billion in 2023, reflecting continued use in surgical anesthesia and neuromuscular-blockade reversal (Merck & Co., 2024). Generic entry places pressure on price and share, but the product’s high clinical utilization and established dosing role preserve substantial market volume.

Revenue erosion is likely to occur in stages:

Stage	Commercial effect
First generic entry	Selective price concessions and hospital contracting
Multiple generic entries	Accelerating price erosion
Broad formulary substitution	Greater branded volume loss
Supply disruption	Temporary recovery of branded or premium generic demand
Device or packaging differentiation	Possible premium segment retention

Key Takeaways

• Sugammadex injection uses a deliberately minimal excipient system: water for injection with hydrochloric acid and/or sodium hydroxide for pH adjustment.
• The best generic formulation strategy is close replication of the reference product at 100 mg/mL.
• Novel buffers, preservatives, and surfactants offer limited value and may increase regulatory risk.
• The main U.S. composition patent estate expired around 2020, with regulatory exclusivity ending around mid-2021 after pediatric extension.
• Sugammadex is a small molecule, so generic ANDA competition applies; biosimilar risk does not.
• Commercial opportunities are strongest in sterile manufacturing, high-purity drug substance, container-closure systems, ready-to-use presentations, and supply reliability.
• Formulation patents are less durable than manufacturing know-how and operational execution.
• Merck’s reported 2023 Bridion sales of approximately $1.5 billion indicate substantial revenue exposure to generic substitution.

FAQs

Is sugammadex compatible with preservatives?

The reference U.S. formulation is a single-dose injectable product without a listed preservative. A preserved multidose formulation would require separate compatibility, sterility, toxicology, and regulatory justification.

Can sugammadex be formulated as a lyophilized product?

Yes, a lyophilized presentation is technically possible, but it would add reconstitution steps and packaging complexity without an obvious advantage over the established aqueous injection.

Are cyclodextrin excipients needed in addition to sugammadex?

Usually not. Sugammadex is itself a modified gamma-cyclodextrin that performs the drug-binding function responsible for reversal of rocuronium and vecuronium.

Does sugammadex have biosimilar competition?

No. Sugammadex is a chemically synthesized small molecule. Competitors pursue generic approval through the ANDA pathway rather than the biosimilar pathway.

What is the highest-value formulation improvement for sugammadex?

A validated prefilled syringe or workflow-optimized single-dose presentation has greater commercial potential than adding a novel excipient to the aqueous formulation.

References

FDA. (2015). Bridion (sugammadex) injection: Original approval package. U.S. Food and Drug Administration.

FDA. (2023a). Bridion (sugammadex) injection prescribing information. U.S. Food and Drug Administration.

FDA. (2023b). Drugs@FDA: Bridion. U.S. Food and Drug Administration.

FDA. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. U.S. Food and Drug Administration.

Merck & Co. (2024). 2023 annual report. Merck & Co., Inc.

U.S. Patent No. 6,670,356. (2003). Modified gamma-cyclodextrins. U.S. Patent and Trademark Office.